A History of Abbott Laboratories MTA
The Story of an S&P 500 Company

About this book:

Abbott Laboratories began in 1888 when Dr. Wallace C. Abbott, a practicing physician in Chicago, founded the Abbott Alkaloidal Company to produce standardized "dosimetric granules," addressing the era's unreliable liquid medicines. This commitment to scientific precision and consistent quality became the company's cornerstone. Abbott navigated the Great Depression and World War II by maintaining R&D investment, culminating in a pivotal role mass-producing penicillin. The post-war era saw aggressive diversification into diagnostics (radiopharmaceuticals, immunoassays), nutrition (acquiring M&R Dietetic Laboratories and Similac in 1964), and medical devices, establishing a broad healthcare portfolio that earned early inclusion in the S&P 500 in 1957.

The late 20th century was defined by the dawn of biotechnology and strategic mergers and acquisitions. Abbott pioneered the first licensed HIV antibody test in 1985 and acquired Knoll Pharmaceuticals in 2001, gaining the blockbuster biologic Humira. Significant acquisitions like Guidant’s vascular business (2006) and St. Jude Medical (2017) solidified leadership in cardiovascular and neuromodulation devices, while innovations like the FreeStyle Libre continuous glucose monitor revolutionized diabetes care. Throughout this period, the company adapted to increasingly complex global regulatory landscapes and deepened its commitment to public health, philanthropy, and expanding access in developing nations.

In 2013, Abbott executed a transformative spin-off of its research-based pharmaceutical business into AbbVie, creating two independent S&P 500 leaders. This allowed the "new" Abbott to sharpen its focus on four core pillars: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals (branded generics). Today, operating in over 160 countries, Abbott leverages this diversified, integrated portfolio to deliver holistic patient care—from rapid COVID-19 diagnostics and structural heart devices to specialized nutrition and essential medicines. Guided by a legacy of scientific rigor and ethical responsibility, Abbott continues to drive growth through digital health integration, personalized medicine, and a commitment to global health equity.

What You'll Find Inside:

• The evolution of Abbott Laboratories from a 1888 Chicago apothecary creating standardized 'dosimetric granules' to a diversified global healthcare leader and S&P 500 stalwart spanning medical devices, diagnostics, nutrition, and established pharmaceuticals.
• Strategic diversification and timely M&A as core growth drivers, including pivotal acquisitions like M&R Dietetic Laboratories (Similac), Knoll Pharmaceuticals (Humira), Guidant's vascular business, and St. Jude Medical, balanced by strategic divestitures such as the AbbVie spin-off.
• A century-long commitment to scientific innovation yielding breakthroughs across eras: from alkaloid standardization and synthetic drugs (barbital) to antibiotics (erythromycin), the first licensed HIV antibody test, biologic therapies (Humira), and connected health solutions (FreeStyle Libre).
• Resilience through adaptive leadership and culture, navigating the Great Depression, WWII penicillin production, evolving regulatory landscapes (1906 Pure Food and Drug Act, 1962 Kefauver-Harris Amendment), and 21st-century challenges like patent cliffs and digital health transformation.
• Integration of social responsibility into business strategy, demonstrated through global public health initiatives (HIV/AIDS diagnostics access, malnutrition programs, COVID-19 rapid response), ethical governance, and a philanthropic model focused on sustainable health system strengthening.

Who's It For:

This book is ideal for business leaders, investors, and healthcare professionals seeking a deep understanding of how a century-old company sustains relevance through strategic reinvention. It will particularly benefit those studying corporate strategy in regulated industries, the history of pharmaceutical and medical device innovation, or the operational complexities of managing a diversified global healthcare portfolio. Students of business history and S&P 500 company evolution will also find the detailed narrative of Abbott's structural transformations, including the AbbVie spin-off, highly instructive.